 |
|
Concurrent Use of Selected Agents With Moxifloxacin: An Examination of Labeling Compliance Within 1 Year of Marketing
Arch Intern Med. 2002;162:2011-2012.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Moxifloxacin is a recently approved fluoroquinolone antibiotic with
indications consistent with outpatient therapy.1
During clinical trials, moxifloxacin was found to prolong the QT interval.
The clinical risk for resulting arrhythmias is unknown, but the approved labeling
includes warnings against concurrent therapy with amiodarone, sotalol hydrochloride,
quinidine, or procainamide hydrochloride. Recent articles2-4
highlight interest in QT prolongation in association with moxifloxacin and
other fluoroquinolones. To proactively study compliance with approved labeling,
we used a large, longitudinal pharmacy claims database to assess concomitant
(overlapping) use of moxifloxacin and levofloxacin (as control) with amiodarone,
sotalol, quinidine, or procainamide. Levofloxacin, initially marketed in January
1997, shares many properties with moxifloxacin but carries no labeled warning
against concurrent therapy with amiodarone, sotalol, quinidine, or procainamide.5
Methods
The data used for this project were from the Quintiles Informatics longitudinal
pharmacy claims database (formerly known as Synergy Healthcare, Waltham, Mass).
At the time of the study, Synergy Healthcare . . . [Full Text of this Article]
Results
Comment
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review
Shrank et al.
The Annals of Pharmacotherapy 2007;41:783-801.
ABSTRACT
| FULL TEXT
Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT
| FULL TEXT
|
